EGFR and non-small cell lung carcinoma: Encouraged by the excellent efficacy of imatinib in the adjuvant treatment for GIST with KIT protein positive expression, oncologists seek to determine whether adjuvant EGFR TKIs treatment could improve the postoperative survival of NSCLC patients.